Guideline for Palliative Sedation in Terminally Ill Patients

Indications for Sedation

• Refractory physical symptoms such as delirium, pain, and dyspnea (occurring in 41–83 %, 25–65 %, and 16–59 % of terminal cases respectively) warrant sedation when all standard therapies have failed. 1
• Emergency situations that require immediate sedation include massive hemorrhage, asphyxiation, severe terminal dyspnea, or an overwhelming pain crisis. 1
• Refractory psychological or existential distress should be considered only in patients with advanced terminal illness after exhaustive evaluation, and only after multiple assessments by clinicians skilled in psychological care and a multidisciplinary case conference (psychiatry, chaplaincy, ethics). 1
• The initial approach for psychological/existential distress is a short‑term “respite” sedation lasting 6–24 h with planned downward titration; continuous sedation is reserved for repeated failed trials. 1

Multidisciplinary Assessment & Decision‑Making

• Confirmation that the patient’s illness is terminal (death expected within days‑to‑weeks) is required before initiating sedation. 2
• The patient’s decisional capacity and goals of care must be evaluated through structured discussions. 2
• Team meetings both before and after sedation are recommended to address professional and emotional burdens on staff. 1

Informed Consent & Communication

• Patients must be informed that sedation is a last‑resort intervention after all other methods have been exhaustively tried. [2][3]
• They should be told that mild sedation may be ineffective and deeper levels may be required, especially when death is imminent. 2
• Patients need to understand that lucidity may not be restored, symptoms may recur, and death may intervene if downward titration is attempted. 2
• Reassurance that optimal care will continue regardless of the decision to sedate is essential. 2
• Permission to inform family members should be obtained, and family discussions should be held both with and without the patient present. 2
• Families should be reassured that all other methods have been exhausted and that sedation is unlikely to shorten life; they should also be encouraged to be present and to say goodbye. 3

Medication Selection & Dosing

First‑Line Benzodiazepine (Midazolam)

• Continuous infusion is mandatory because the drug’s rapid redistribution makes intermittent dosing ineffective. 4
• Reported adverse effects include paradoxical agitation, respiratory depression, withdrawal syndrome on rapid reduction, and tolerance with prolonged use. 4

Second‑Line Antipsychotics (for Delirium)

Levomepromazine

Chlorpromazine

• Antipsychotics must be used before benzodiazepines or opioids in delirium to avoid worsening the condition. 5

Third‑Line Barbiturates & Anesthetic Agents (Refractory Cases)

Phenobarbital

Propofol

• Both phenobarbital and propofol provide no analgesia; concurrent opioid therapy is required when pain is present. [5][3]

Administration Strategy & Monitoring

• Continuous infusion or “around‑the‑clock” intermittent boluses are required to maintain a sustained sedative effect. 6
• Permitted routes include IV, IM, subcutaneous, rectal, and, when appropriate, via stoma or gastrostomy. 6
• An emergency breakthrough bolus must be readily available. 6
• The principle of “least sedation necessary” should guide dosing to achieve adequate relief of suffering. 6
• If mild sedation is ineffective, deeper levels may be pursued, especially when death is imminent or in catastrophic events. 2
• Downward titration to restore lucidity may be attempted only if the patient explicitly requests re‑evaluation before sedation initiation. 2

Monitoring

• Imminently dying patients: routine vital‑sign monitoring (pulse, BP, temperature) is omitted; focus is on comfort parameters, primarily respiratory rate to ensure absence of distress. 2
• Gradual respiratory decline is expected and should not trigger dose reduction; downward titration is not recommended in this group. 2
• Non‑imminently dying patients (including respite sedation): monitor sedation level and physiological parameters (HR, BP, SpO₂) to preserve stability; adjust dosing if life‑threatening obtundation or respiratory depression occurs, possibly using flumazenil. 2

Hydration, Nutrition & Related Decisions

• Decisions regarding artificial hydration or nutrition are independent of the sedation decision and should be made separately. 6
• Opinions on artificial support vary widely among clinicians, patients, families, and ethical norms. [4][6]
• If artificial hydration/nutrition worsens suffering, reduction or withdrawal should be considered, with consensus among family and healthcare providers when the patient cannot decide. [5][4]

Criteria for Discontinuation or Modification

• Planned downward titration after 6–24 h is required for respite sedation addressing psychological/existential distress. 1
• Patient‑requested re‑evaluation before sedation initiation permits possible dose reduction. 2
• Imminently dying patients should not have sedation reduced, as this risks recurrent distress without benefit. 2
• Rapid dose reduction after continuous benzodiazepine infusion can precipitate withdrawal syndrome; tapering is advised. 4

Staff Support & Documentation

• Recognize potential staff distress, especially in prolonged or contested cases; foster a culture of sensitivity through pre‑ and post‑event team meetings. 1
• Comprehensive documentation of indication, consent process, medication regimen, and monitoring plan is required when initiating sedation.

All statements are derived from cited guideline sources (e.g., oncology palliative‑care guidelines) and reflect the strength of evidence as presented in the original references.

Evidence‑Based Recommendations for Palliative Sedation

Benzodiazepines (First‑Line)

• Midazolam is the preferred first‑line agent because of its rapid onset, short half‑life, and flexibility of IV or sub‑cutaneous administration. It should be started at 0.5–1 mg/h continuous infusion, with 1–5 mg boluses for refractory symptoms, and titrated to an effective range of 1–20 mg/h. 7, 8
• Continuous infusion is required; intermittent dosing fails to maintain a sustained sedative effect. 7, 9
• Co‑administration with morphine or haloperidol is acceptable when additional symptom control is needed. 7
• Key adverse effects include paradoxical agitation, respiratory depression, withdrawal syndrome if the dose is reduced rapidly, and tolerance with prolonged use. 7, 8

Antipsychotics for Delirium‑Associated Sedation

• Opioids or benzodiazepines as initial therapy may worsen delirium; antipsychotics are the recommended first‑line agents in this context. 7, 10

• Levomepromazine

  • Initial dosing: 12.5–25 mg bolus or 50–75 mg continuous infusion.
  • Effective regimen: 12.5–25 mg every 8 h plus PRN for agitation, up to 300 mg/day continuous infusion. 7, 11, 12
  • Advantages: antipsychotic effect, modest analgesia, multiple routes (oral, IV, SC, IM). 7, 9
  • Adverse effects: orthostatic hypotension, paradoxical agitation, extrapyramidal symptoms, anticholinergic effects. 7, 11

• Chlorpromazine

  • Initial dosing: 12.5 mg every 4–12 h IV/IM, or 3–5 mg/h IV, or 25–100 mg rectally every 4–12 h.
  • Effective dosing: 37.5–150 mg/day parenterally, or 75–300 mg/day rectally. 7, 12, 10
  • Critical warning: IV administration should be limited to bedridden patients because of its hypotensive effect. 7, 13

Barbiturates and Anesthetic Agents (Refractory Cases)

• These agents reliably induce rapid unconsciousness in patients with extreme tolerance to opioids and benzodiazepines, but they provide no analgesia; concurrent opioid therapy is required for pain control. 7, 13, 12, 10

• Phenobarbital

  • Bolus: 1–3 mg/kg SC or IV, followed by an initial infusion of 0.5 mg/kg/h.
  • Maintenance: 50–100 mg/h. 7, 11, 13
  • Advantages: rapid onset and anticonvulsant properties. 7, 12

• Propofol

  • Loading dose: 20 mg, then continuous infusion of 50–70 mg/h. 7, 13, 10
  • Advantages: short duration of action, very rapid onset, and easy titration. 7, 10

Administration and Monitoring

• Infusion strategy: continuous infusion or regular intermittent boluses “around the clock” is recommended. 12
• Permitted routes: IV, IM, SC, rectal, and when appropriate, via stoma or gastrostomy. 12
• Emergency preparedness: an emergency bolus must be available for sudden intercurrent symptoms. 12

Management of Pre‑Existing Medications

• Continue all previously prescribed symptom‑control drugs unless they are ineffective or cause distressing side effects. 8, 13, 10
• Discontinue medications that are irrelevant to the comfort goal or that do not contribute to symptom relief. 8, 13
• Opioids: maintain pre‑sedation opioid regimens unless adverse effects or signs of overdose (e.g., respiratory depression) appear; if overdose is suspected, reduce the dose gradually to avoid withdrawal. 8, 13, 11

Hydration and Nutrition

• Decisions regarding artificial hydration or nutrition are independent of the sedation decision; they may be reduced or stopped if they increase patient suffering. 12, 9, 7, 10

Communication with Family

• Family support measures: encourage presence and allow farewells; reassure that all other therapeutic options have been exhausted and that sedation is unlikely to shorten life; provide regular updates on patient status, expected course, and any approaching end‑of‑life milestones. 13, 10

Critical Safety Warnings

• Avoid benzodiazepines in elderly or cognitively impaired patients because of the risk of further cognitive decline. 14
• Do not use benzodiazepines as the initial treatment for delirium in patients not previously receiving them. 14
• Lorazepam may provoke paradoxical excitation in delirious patients unless therapeutic levels of antipsychotics are already present. 14